Sitagliptin (MK 0431) for type 2 diabetes - horizon scanning review
NHSC
Record Status
This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database.
Citation
NHSC. Sitagliptin (MK 0431) for type 2 diabetes - horizon scanning review. Birmingham: National Horizon Scanning Centre (NHSC). 2005
Authors' objectives
This study aims to assess the effectiveness of sitagliptin (MK 0431) for type 2 diabetes.
Authors' conclusions
Sitagliptin (MK 0431) belongs to the new class of incretin enhancer drugs that also includes LAF237 (Vildagliptin) and exenatide. Sitagliptin is administered orally and is in clinical trials in addition to, and as a substitute for, current glucose-lowering therapies in patients with type 2 diabetes. Phase II clinical trials demonstrated that sitagliptin in the short-term significantly improved glycaemic control in patients with type 2 diabetes compared to placebo (two studies) and with metformin (one study). Several phase III studies are currently underway.
Diabetes Mellitus, Type 2 /drug therapy; Hypoglycemic Agents
Language Published
English
Country of organisation
England
English summary
An English language summary is available.
Address for correspondence
Department of Public Health&Epidemiology, The University of Birmingham, Edgbaston, Birmingham B15 2TT, United Kingdom. Tel: +44 121 414 7831; Fax: +44 121 414 2269; Email: c.packer@bham.ac.uk